105 results
8-K
EX-99.2
VANI
Vivani Medical Inc
26 Mar 24
Vivani Medical Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
8:31am
pre - clinical activities of our other products; our products may not demonstrate safety or efficacy in clinical trials; we may fail to secure … CRL (cited clinical safety and device constituent concerns) 2022 – After dispute resolutions, FDA’s CDER proposes to deny Intarcia’s public hearing
8-K
EX-99.1
VANI
Vivani Medical Inc
5 Mar 24
Vivani Medical Announces Pricing of $15.0 Million Registered Direct Offering of Common Stock and Warrants
4:21pm
investigation of the safety, tolerability, and full pharmacokinetic profile of NPM-119 in patients with type 2 diabetes. Vivani is also preparing to submit
8-K
EX-10.1
VANI
Vivani Medical Inc
5 Mar 24
Vivani Medical Announces Pricing of $15.0 Million Registered Direct Offering of Common Stock and Warrants
4:21pm
to taxes, environmental protection, occupational health and safety, product quality and safety and employment and labor matters, except in each case
8-K
EX-99.2
x43rgf4 58
28 Feb 24
Regulation FD Disclosure
8:30am
8-K
EX-99.1
u49 ot4qklbicm4
28 Feb 24
Regulation FD Disclosure
8:30am
8-K
EX-99.2
jdjs 9xthkk44lo
14 Nov 23
Results of Operations and Financial Condition
6:06am
8-K
EX-99.1
pp9ql49 0lys
14 Nov 23
Results of Operations and Financial Condition
6:06am
8-K
EX-99.1
j6kj2i6x3wv lyujli3
18 Sep 23
Regulation FD Disclosure
6:20am
8-K
EX-99.1
skyik
28 Aug 23
Entry into a Material Definitive Agreement
5:43pm
8-K
EX-3.2
jdjz 4zf3up
10 Jul 23
Material Modifications to Rights of Security Holders
4:04pm
8-K
EX-99.2
262yw
15 May 23
Results of Operations and Financial Condition
6:49am
8-K
EX-99.1
m1110dc
15 May 23
Results of Operations and Financial Condition
6:49am
DEFR14A
qbtv8p nys8sv
1 May 23
Revised proxy
4:49pm